A Review: Diagnosis and Treatment of Monkeypox Patients
Sebuah Tinjauan: Diagnosis dan Pengobatan Pasien Cacar Monyet
DOI:
https://doi.org/10.21070/ijhsm.v1i2.24Keywords:
Mpox, Health problem, Infection, Diagnosis and treatmentAbstract
A viral illness impacting children and young adults, it commences gradually and the infection can be minor. A significant proportion of patients progress to the acute stage of the infection. The condition progresses in the acute phase to encephalitis, myocarditis, pneumonia, and ocular complications in severe instances. The monkeypox viral infection constitutes a significant global public health issue. The nation carries the highest burden of monkeypox infections internationally and will significantly contribute to the eradication of this disease worldwide. Despite the country's significant advancements in mitigating monkeypox virus infections in prior years, Iraq currently encounters obstacles in its objective to diminish the fatality and morbidity rates associated with monkeypox. In alignment with the WHO global health sector policy on monkeypox, we emphasise additional priority for action to eradicate this virus in Iraq, aiming to accomplish the objective of lowering death, and we recommend prioritising service coverage targets for diagnosis and treatment. Initially, it is essential to enhance the diagnostic and therapeutic capabilities of medical facilities and healthcare professionals. Secondly, the government must alleviate the financial strain of healthcare on patients. Third, improved coordination of current national initiatives and resources is essential to create an integrated prevention and control system encompassing the prevention, screening, diagnosis, and treatment of HIV infection and monkeypox across the life cycle. Thus, advancement can be achieved in the objective of eradicating monkeypox in Iraq.
Highlights:
- Gradual onset illness affecting children, causing severe complications in acute stage.
- Iraq faces challenges in reducing monkeypox fatality and morbidity rates.
- Focus: Enhance healthcare, ease costs, and improve prevention coordination.
Keywords: Mpox, Health problem, Infection, Diagnosis and treatment.
References
R. Arbel, Y. Wolff Sagy, R. Zucker, N. Arieh, W. Wiessam, E. Battat, et al., “Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study,” 2022.
A. W. Rimoin, P. M. Mulembakani, S. C. Johnston, J. O. Lloyd-Smith, N. K. Kisalu, T. L. Kinkela, et al., “Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo,” Proc. Natl. Acad. Sci. U. S. A., vol. 107, pp. 16262–16267, 2010, doi: 10.1073/pnas.1005769107.
T. Saito, T. Fujii, Y. Kanatani, M. Saijo, S. Morikawa, and H. Yokote, et al., “Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8,” JAMA, vol. 301, pp. 1025–1033, 2009, doi: 10.1001/jama.2009.289.
Y. Nishiyama, T. Fujii, Y. Kanatani, Y. Shinmura, H. Yokote, and S. Hashizume, “Freeze-dried live attenuated smallpox vaccine prepared in cell culture ‘LC16-KAKETSUKEN’: Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice,” Vaccine, vol. 33, pp. 6120–6127, 2015, doi: 10.1016/j.vaccine.2015.09.067.
J. S. Kennedy, M. Gurwith, C. L. Dekker, S. E. Frey, K. M. Edwards, and J. Kenner, et al., “Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults,” J. Infect. Dis., vol. 204, pp. 1395–1402, 2011, doi: 10.1093/infdis/jir527.
P. R. Pittman, M. Hahn, H. S. Lee, C. Koca, N. Samy, and D. Schmidt, et al., “Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox,” N. Engl. J. Med., vol. 381, pp. 1897–1908, 2019, doi: 10.1056/NEJMoa1817307.
S. R. Walsh, M. B. Wilck, D. J. Dominguez, E. Zablowsky, S. Bajimaya, and L. S. Gagne, et al., “Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: A randomized, controlled trial,” J. Infect. Dis., vol. 207, pp. 1888–1897, 2013, doi: 10.1093/infdis/jit105.
E. T. Overton, S. J. Lawrence, J. T. Stapleton, H. Weidenthaler, D. Schmidt, and B. Koenen, et al., “A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS,” Vaccine, vol. 38, pp. 2600–2607, 2020, doi: 10.1016/j.vaccine.2020.01.058.
S. E. Frey, A. Wald, S. Edupuganti, L. A. Jackson, J. T. Stapleton, and H. El Sahly, et al., “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects,” Vaccine, vol. 33, pp. 5225–5234, 2015, doi: 10.1016/j.vaccine.2015.06.075.
S. A. Sarkisian, et al., “A case series of smallpox vaccination-associated myopericarditis: Effects on safety and readiness of the active duty soldier,” Mil. Med., vol. 184, no. 1–2, pp. e280–e283, 2019, doi: 10.1093/milmed/usy159.
C. Pugh, et al., “Povidone iodine ointment application to the vaccination site does not alter immunoglobulin G antibody response to smallpox vaccine,” Viral Immunol., vol. 29, no. 6, pp. 361–366, 2016, doi: 10.1089/vim.2016.0025.
A. Berhanu, et al., “Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection,” Antimicrob. Agents Chemother., vol. 59, no. 7, pp. 4296–4300, 2015, doi: 10.1128/AAC.00208-15.
A. M. Mandra, et al., “Myopericarditis associated with smallpox vaccination among US army personnel – Fort Hood, Texas, 2018,” Disaster Med. Public Health Prep., vol. 15, pp. 1–7, Mar. 2021, doi: 10.1017/dmp.2020.478.
L. A. Jackson, et al., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial,” Vaccine, vol. 35, no. 13, pp. 1675–1682, Mar. 2017, doi: 10.1016/j.vaccine.2017.02.032.
J. S. Kennedy, “Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults,” J. Infect. Dis., vol. 204, no. 9, pp. 1395–1402, Nov. 2011, doi: 10.1093/infdis/jir527.
